Gilbert PB - Search Results

1

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.

Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, Noriega F, Gilbert PB. Moodie Z, et al. Among authors: gilbert pb. J Infect Dis. 2018 Feb 14;217(5):742-753. doi: 10.1093/infdis/jix609. J Infect Dis. 2018. PMID: 29194547 Free PMC article. Clinical Trial.

2

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Gilbert PB, Self SG, Ashby MA. Gilbert PB, et al. Biometrics. 1998 Sep;54(3):799-814. Biometrics. 1998. PMID: 9750238

3

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

Gilbert P, Self S, Rao M, Naficy A, Clemens J. Gilbert P, et al. J Clin Epidemiol. 2001 Jan;54(1):68-85. doi: 10.1016/s0895-4356(00)00258-4. J Clin Epidemiol. 2001. PMID: 11165470 Review.

4

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

5

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: gilbert pb. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

6

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Lee D, et al. Among authors: gilbert pb. J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29. J Infect Dis. 2004. PMID: 15295694 Clinical Trial.

7

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

8

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. Gilbert PB, et al. J Infect Dis. 2005 Sep 15;192(6):974-83. doi: 10.1086/432734. Epub 2005 Aug 12. J Infect Dis. 2005. PMID: 16107949 Clinical Trial.

9

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND. Moodie Z, et al. Among authors: gilbert pb. Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19. Contemp Clin Trials. 2006. PMID: 16426900

10

On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.

Wick WD, Gilbert PB, Self SG. Wick WD, et al. Among authors: gilbert pb. PLoS Comput Biol. 2006 Jun 16;2(6):e64. doi: 10.1371/journal.pcbi.0020064. Epub 2006 Jun 16. PLoS Comput Biol. 2006. PMID: 16789816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters